Neuroprotective action of halogenated derivatives of L-Phenylalanine
The aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission (GST) via a unique set of presynaptic and postsynaptic mechanisms. Therefore, we hypothesized that endogenous derivatives of L-Phe, which display potent antiglutamate...
Saved in:
Published in: | Stroke (1970) Vol. 35; no. 5; pp. 1192 - 1196 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Hagerstown, MD
Lippincott Williams & Wilkins
01-05-2004
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | The aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission (GST) via a unique set of presynaptic and postsynaptic mechanisms. Therefore, we hypothesized that endogenous derivatives of L-Phe, which display potent antiglutamatergic activity, may safely and efficaciously protect the brain during conditions characterized by overactivation of glutamate receptors.
We tested this hypothesis in vitro with a combination of patch-clamp and lactate dehydrogenase (LDH) analyses in rat cultured neurons exposed to simulated ischemia, and in vivo using a rat model of experimental stroke caused by transient middle cerebral artery occlusion (MCAO).
3,5-diiodo-L-tyrosine (DIT) and 3,5-dibromo-L-tyrosine (DBrT), endogenous halogenated derivatives of L-Phe, attenuated GST by similar mechanisms as L-Phe, but with greater potency. For example, the IC50s for DIT and DBrT to depress the frequency of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)/kainate receptor-mediated mEPSCs were 104.6+/-14.1 micromol/L and 127.5+/-13.3 micromol/L, respectively. Depression of GST by DIT and DBrT persisted during energy deprivation. Furthermore, DBrT significantly reduced LDH release in neuronal cultures exposed to oxygen glucose deprivation. In rats subjected to transient MCAO, DBrT decreased the brain infarct volume and neurological deficit score to 52.7+/-14.1% and 57.1+/-12.0% of control values, respectively. DBrT neither altered atrioventricular nodal and intraventricular conduction in isolated heart, nor heart rate and blood pressure in vivo.
DBrT, an endogenous halogenated derivative of L-Phe, shows promise as a representative of a novel class of neuroprotective agents by exerting significant neuroprotection in both in vitro and in vivo models of brain ischemia. |
---|---|
AbstractList | BACKGROUND AND PURPOSEThe aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission (GST) via a unique set of presynaptic and postsynaptic mechanisms. Therefore, we hypothesized that endogenous derivatives of L-Phe, which display potent antiglutamatergic activity, may safely and efficaciously protect the brain during conditions characterized by overactivation of glutamate receptors.METHODSWe tested this hypothesis in vitro with a combination of patch-clamp and lactate dehydrogenase (LDH) analyses in rat cultured neurons exposed to simulated ischemia, and in vivo using a rat model of experimental stroke caused by transient middle cerebral artery occlusion (MCAO).RESULTS3,5-diiodo-L-tyrosine (DIT) and 3,5-dibromo-L-tyrosine (DBrT), endogenous halogenated derivatives of L-Phe, attenuated GST by similar mechanisms as L-Phe, but with greater potency. For example, the IC50s for DIT and DBrT to depress the frequency of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)/kainate receptor-mediated mEPSCs were 104.6+/-14.1 micromol/L and 127.5+/-13.3 micromol/L, respectively. Depression of GST by DIT and DBrT persisted during energy deprivation. Furthermore, DBrT significantly reduced LDH release in neuronal cultures exposed to oxygen glucose deprivation. In rats subjected to transient MCAO, DBrT decreased the brain infarct volume and neurological deficit score to 52.7+/-14.1% and 57.1+/-12.0% of control values, respectively. DBrT neither altered atrioventricular nodal and intraventricular conduction in isolated heart, nor heart rate and blood pressure in vivo.CONCLUSIONSDBrT, an endogenous halogenated derivative of L-Phe, shows promise as a representative of a novel class of neuroprotective agents by exerting significant neuroprotection in both in vitro and in vivo models of brain ischemia. Background and Purpose— The aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission (GST) via a unique set of presynaptic and postsynaptic mechanisms. Therefore, we hypothesized that endogenous derivatives of L-Phe, which display potent antiglutamatergic activity, may safely and efficaciously protect the brain during conditions characterized by overactivation of glutamate receptors. Methods— We tested this hypothesis in vitro with a combination of patch-clamp and lactate dehydrogenase (LDH) analyses in rat cultured neurons exposed to simulated ischemia, and in vivo using a rat model of experimental stroke caused by transient middle cerebral artery occlusion (MCAO). Results— 3,5-diiodo- l -tyrosine (DIT) and 3,5-dibromo- l -tyrosine (DBrT), endogenous halogenated derivatives of L-Phe, attenuated GST by similar mechanisms as L-Phe, but with greater potency. For example, the IC 50 s for DIT and DBrT to depress the frequency of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)/kainate receptor-mediated mEPSCs were 104.6±14.1 μmol/L and 127.5±13.3 μmol/L, respectively. Depression of GST by DIT and DBrT persisted during energy deprivation. Furthermore, DBrT significantly reduced LDH release in neuronal cultures exposed to oxygen glucose deprivation. In rats subjected to transient MCAO, DBrT decreased the brain infarct volume and neurological deficit score to 52.7±14.1% and 57.1±12.0% of control values, respectively. DBrT neither altered atrioventricular nodal and intraventricular conduction in isolated heart, nor heart rate and blood pressure in vivo. Conclusions— DBrT, an endogenous halogenated derivative of L-Phe, shows promise as a representative of a novel class of neuroprotective agents by exerting significant neuroprotection in both in vitro and in vivo models of brain ischemia. The aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission (GST) via a unique set of presynaptic and postsynaptic mechanisms. Therefore, we hypothesized that endogenous derivatives of L-Phe, which display potent antiglutamatergic activity, may safely and efficaciously protect the brain during conditions characterized by overactivation of glutamate receptors. We tested this hypothesis in vitro with a combination of patch-clamp and lactate dehydrogenase (LDH) analyses in rat cultured neurons exposed to simulated ischemia, and in vivo using a rat model of experimental stroke caused by transient middle cerebral artery occlusion (MCAO). 3,5-diiodo-L-tyrosine (DIT) and 3,5-dibromo-L-tyrosine (DBrT), endogenous halogenated derivatives of L-Phe, attenuated GST by similar mechanisms as L-Phe, but with greater potency. For example, the IC50s for DIT and DBrT to depress the frequency of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)/kainate receptor-mediated mEPSCs were 104.6+/-14.1 micromol/L and 127.5+/-13.3 micromol/L, respectively. Depression of GST by DIT and DBrT persisted during energy deprivation. Furthermore, DBrT significantly reduced LDH release in neuronal cultures exposed to oxygen glucose deprivation. In rats subjected to transient MCAO, DBrT decreased the brain infarct volume and neurological deficit score to 52.7+/-14.1% and 57.1+/-12.0% of control values, respectively. DBrT neither altered atrioventricular nodal and intraventricular conduction in isolated heart, nor heart rate and blood pressure in vivo. DBrT, an endogenous halogenated derivative of L-Phe, shows promise as a representative of a novel class of neuroprotective agents by exerting significant neuroprotection in both in vitro and in vivo models of brain ischemia. |
Author | SEUBERT, Christoph N MARTYNYUK, Anatoly E ROOSE, Brandy KAGIYAMA, Tomoko DENNIS, Donn M PHILLIPS, M. Ian GLUSHAKOV, Alexander V SUMNERS, Colin OZCAN, Mehmet S |
Author_xml | – sequence: 1 givenname: Tomoko surname: KAGIYAMA fullname: KAGIYAMA, Tomoko organization: Department of Physiology and Functional Genomics, University of Florida, Gainesville, Fla, United States – sequence: 2 givenname: Alexander V surname: GLUSHAKOV fullname: GLUSHAKOV, Alexander V organization: Department of Anesthesiology, University of Florida, Gainesville, Fla, United States – sequence: 3 givenname: Colin surname: SUMNERS fullname: SUMNERS, Colin organization: Department of Physiology and Functional Genomics, University of Florida, Gainesville, Fla, United States – sequence: 4 givenname: Brandy surname: ROOSE fullname: ROOSE, Brandy organization: Department of Physiology and Functional Genomics, University of Florida, Gainesville, Fla, United States – sequence: 5 givenname: Donn M surname: DENNIS fullname: DENNIS, Donn M organization: Department of Anesthesiology, University of Florida, Gainesville, Fla, United States – sequence: 6 givenname: M. Ian surname: PHILLIPS fullname: PHILLIPS, M. Ian organization: Department of Physiology and Functional Genomics, University of Florida, Gainesville, Fla, United States – sequence: 7 givenname: Mehmet S surname: OZCAN fullname: OZCAN, Mehmet S organization: Department of Anesthesiology, University of Florida, Gainesville, Fla, United States – sequence: 8 givenname: Christoph N surname: SEUBERT fullname: SEUBERT, Christoph N organization: Department of Anesthesiology, University of Florida, Gainesville, Fla, United States – sequence: 9 givenname: Anatoly E surname: MARTYNYUK fullname: MARTYNYUK, Anatoly E organization: Department of Anesthesiology, University of Florida, Gainesville, Fla, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15723999$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/15073406$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkNtKw0AQhhep2IO-ggRB7xL3kM1mvZN6hKKi9XqZbiY2kiY1mxT69m5toM7NXMw3Mz_fmAyqukJCLhiNGEvYNWXRx_w9or4Yl4rziNGEJhFVR2TEJI_DOOHpgIwoFTrksdZDMnbu2_NcpPKEDJmkSsQ0GZG7F-yaet3ULdq22GAAvtVVUOfBEsr6CytoMQsybIoN7AC3G83CtyVW2xJKqIoKT8lxDqXDs75PyOfD_Xz6FM5eH5-nt7PQyli1oc2TzPIkXySCZwvLOc1SjcBFboGKFHgaA8-YYFZIBBAWMytzVLFQEjClYkKu9nd93p8OXWtWhbNY-hRYd84olkolU-3Bmz1om9q5BnOzbooVNFvDqNk5NJQZ79AcHJo_h8Z7mZDz_ku3WGF2WO2leeCyB8BZKPMGKlu4f5ziQmstfgGSG31R |
CODEN | SJCCA7 |
CitedBy_id | crossref_primary_10_1113_expphysiol_2011_058578 crossref_primary_10_3390_antiox10081168 crossref_primary_10_1016_j_neuropharm_2014_01_044 crossref_primary_10_1007_s11306_019_1615_1 crossref_primary_10_1080_10715762_2019_1668560 crossref_primary_10_3390_metabo9100240 crossref_primary_10_1039_C5RA19934D crossref_primary_10_3389_fmolb_2021_630291 crossref_primary_10_1039_C6MB00137H crossref_primary_10_1038_jcbfm_2012_198 crossref_primary_10_1021_acs_jproteome_1c00406 crossref_primary_10_1080_08941930591004449 crossref_primary_10_1039_C5MB00470E crossref_primary_10_1113_expphysiol_2009_047936 crossref_primary_10_1016_j_freeradbiomed_2013_08_166 crossref_primary_10_1124_mol_104_005983 crossref_primary_10_5853_jos_2018_03454 crossref_primary_10_1016_j_taap_2020_115140 crossref_primary_10_1002_jnr_24226 crossref_primary_10_1038_sj_cdd_4402189 crossref_primary_10_1039_c3mb70040b crossref_primary_10_1002_jlcr_4057 crossref_primary_10_1016_S0254_6272_18_30906_3 crossref_primary_10_1016_j_arr_2022_101730 crossref_primary_10_1016_j_ymgme_2005_06_014 crossref_primary_10_3389_fnins_2021_701355 crossref_primary_10_1007_s11055_013_9832_y crossref_primary_10_1515_revneuro_2021_0048 |
Cites_doi | 10.1159/000049127 10.1161/str.24.1.8418534 10.1161/01.RES.63.1.97 10.1038/sj.mp.4000976 10.1152/physrev.1999.79.4.1431 10.1016/S0031-9384(00)00276-6 10.1161/str.20.1.2643202 10.1097/00004647-200005000-00003 10.1185/030079902125000660 10.1038/nn936 10.1172/JCI111695 10.1089/105072501300176363 10.1523/JNEUROSCI.22-04-01273.2002 10.1124/mol.51.5.733 10.1161/str.26.11.2187 10.1002/jnr.10569 10.3995/jstroke.8.1 10.1021/bi982401l |
ContentType | Journal Article |
Copyright | 2004 INIST-CNRS |
Copyright_xml | – notice: 2004 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1161/01.STR.0000125722.10606.07 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1524-4628 |
EndPage | 1196 |
ExternalDocumentID | 10_1161_01_STR_0000125722_10606_07 15073406 15723999 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .3C .55 .GJ .XZ .Z2 01R 08R 0R~ 123 1J1 2WC 3O- 40H 4Q1 4Q2 4Q3 53G 5RE 5VS 6PF 71W 77Y 7O~ A9M AAAXR AAGIX AAHPQ AAJCS AAMOA AAMTA AAPBV AAQKA AAQQT AARTV AASOK AAUGY AAXQO AAYEP AAYJJ ABASU ABBUW ABDIG ABQRW ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFS ACGOD ACILI ACWDW ACWRI ACXNZ ADBBV ADFPA ADGGA ADNKB AE3 AE6 AEBDS AEETU AENEX AFDTB AFFNX AFUWQ AGINI AHMBA AHOMT AHRYX AHVBC AIJEX AJIOK AJNWD AJNYG AKALU AKULP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM AYCSE BAWUL BCGUY BOYCO BQLVK BS7 C45 CS3 DIK DIWNM DU5 DUNZO E.X E3Z EBS EEVPB EJD EX3 F2K F2L F2M F2N F5P FCALG FL- FW0 GNXGY GQDEL GX1 H0~ H13 HZ~ IKREB IKYAY IN~ IPNFZ IQODW J5H JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C L7B M18 N4W N9A N~7 N~B N~M O9- OAG OAH OB3 OCUKA ODA ODMTH OGROG OHYEH OJAPA OK1 OL1 OLG OLH OLU OLV OLW OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQQKQ R58 RAH RHF RIG RLZ S4R S4S T8P TEORI TSPGW TWZ V2I VVN W3M W8F WH7 WOQ WOW X3V X3W X7M XXN XYM YCJ YFH YHZ YQJ YYP ZA5 ZB8 ZGI ZZMQN AAAAV AAIQE AASCR AAUEB ABJNI ABVCZ ACLDA ACXJB ADHPY AFEXH AFSOK AHQNM AINUH AJZMW CGR CUY CVF ECM EIF ERAAH HLJTE NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c547t-cf6dc26fb632dbc220d89ea23fca038a284a2d131c35eaa3cedc5fe74375ae803 |
ISSN | 0039-2499 |
IngestDate | Sat Aug 17 00:05:05 EDT 2024 Fri Nov 22 01:07:07 EST 2024 Tue Oct 15 23:28:14 EDT 2024 Sun Oct 22 16:04:11 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Stroke Nervous system diseases Phenylalanine Cardiovascular disease Glutamate receptor Glutamate excitotuxicity Cerebral disorder Vascular disease Aminoacid neuroprotection Central nervous system disease receptors, glutamate Antidepressant agent Cerebrovascular disease |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c547t-cf6dc26fb632dbc220d89ea23fca038a284a2d131c35eaa3cedc5fe74375ae803 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doi.org/10.1161/01.str.0000125722.10606.07 |
PMID | 15073406 |
PQID | 71857589 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_71857589 crossref_primary_10_1161_01_STR_0000125722_10606_07 pubmed_primary_15073406 pascalfrancis_primary_15723999 |
PublicationCentury | 2000 |
PublicationDate | 2004-05-01 |
PublicationDateYYYYMMDD | 2004-05-01 |
PublicationDate_xml | – month: 05 year: 2004 text: 2004-05-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Hagerstown, MD |
PublicationPlace_xml | – name: Hagerstown, MD – name: United States |
PublicationTitle | Stroke (1970) |
PublicationTitleAlternate | Stroke |
PublicationYear | 2004 |
Publisher | Lippincott Williams & Wilkins |
Publisher_xml | – name: Lippincott Williams & Wilkins |
References | e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_19_2 e_1_3_2_1_2 e_1_3_2_10_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_2_2 e_1_3_2_14_2 |
References_xml | – ident: e_1_3_2_4_2 doi: 10.1159/000049127 – ident: e_1_3_2_14_2 doi: 10.1161/str.24.1.8418534 – ident: e_1_3_2_15_2 – ident: e_1_3_2_11_2 doi: 10.1161/01.RES.63.1.97 – ident: e_1_3_2_7_2 doi: 10.1038/sj.mp.4000976 – ident: e_1_3_2_19_2 doi: 10.1152/physrev.1999.79.4.1431 – ident: e_1_3_2_18_2 doi: 10.1016/S0031-9384(00)00276-6 – ident: e_1_3_2_13_2 doi: 10.1161/str.20.1.2643202 – ident: e_1_3_2_5_2 doi: 10.1097/00004647-200005000-00003 – ident: e_1_3_2_6_2 doi: 10.1185/030079902125000660 – ident: e_1_3_2_2_2 doi: 10.1038/nn936 – ident: e_1_3_2_9_2 doi: 10.1172/JCI111695 – ident: e_1_3_2_17_2 doi: 10.1089/105072501300176363 – ident: e_1_3_2_3_2 doi: 10.1523/JNEUROSCI.22-04-01273.2002 – ident: e_1_3_2_10_2 doi: 10.1124/mol.51.5.733 – ident: e_1_3_2_1_2 doi: 10.1161/str.26.11.2187 – ident: e_1_3_2_8_2 doi: 10.1002/jnr.10569 – ident: e_1_3_2_12_2 doi: 10.3995/jstroke.8.1 – ident: e_1_3_2_16_2 doi: 10.1021/bi982401l |
SSID | ssj0002385 |
Score | 1.9679595 |
Snippet | The aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission (GST) via a unique set of... Background and Purpose— The aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission... BACKGROUND AND PURPOSEThe aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission... |
SourceID | proquest crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 1192 |
SubjectTerms | Animals Biological and medical sciences Disease Models, Animal In Vitro Techniques Infarction, Middle Cerebral Artery - drug therapy Infarction, Middle Cerebral Artery - prevention & control L-Lactate Dehydrogenase - metabolism Male Medical sciences Neurology Neurons - enzymology Neuroprotective Agents - pharmacology Neuroprotective Agents - therapeutic use Patch-Clamp Techniques Phenylalanine - analogs & derivatives Phenylalanine - pharmacology Phenylalanine - therapeutic use Rats Rats, Sprague-Dawley Receptors, Glutamate - drug effects Receptors, Glutamate - physiology Stroke - drug therapy Stroke - metabolism Stroke - pathology Synaptic Transmission - drug effects Synaptic Transmission - physiology Tyrosine - analogs & derivatives Tyrosine - pharmacology Tyrosine - therapeutic use Vascular diseases and vascular malformations of the nervous system |
Title | Neuroprotective action of halogenated derivatives of L-Phenylalanine |
URI | https://www.ncbi.nlm.nih.gov/pubmed/15073406 https://search.proquest.com/docview/71857589 |
Volume | 35 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9swEBdpC2Mwxr6XfXR-2KszWfKXHtsmobCsg8WFvglFH9tIY5cmLvS_30mWY6esbHvYi0kUywl3l7vfSaffIfRRMUYM4NRQSkPDGLLakGmNw0Rjhk2mdeJ4Ck7n2dlFPp7Ek8Gg3T3vxv6rpmEMdG1Pzv6DtrcPhQF4DTqHK2gdrn-ld8e24dkXbFWQ7wVuMaFdp9GlsBhTwU-5cZzfrpRjFtpSr9tLW-fYbrR7xDrfXFdLB0QjluHewsFn8f3nrVg58FlUq2pZbWt5Luv1D7GsbnZO0HTltPN6VfrWbCe2Z1C36ePbPB5DAPWkt-2CRNyV_420d6IkDu2Z176XbUhJvDUlPZcZRU0zPB9-4W36e9eeRu64wmhefHOskwDNMkJGkNM6AtYuoLWb-Gdf-fR8NuPF5KLYQwcEXBF4woOj6bg43kZrgCyJJ6OFb_h0__N3gMujK7GG_5Bpmp_cn504lFI8QY99ehEcNXbxFA10-Qw9-OILKJ6j8R3zCBrzCCoT9Mwj6JmH_eiOebxA59NJcXIa-kYaoUzibBNKkypJUrNIKVELSQhWOdOCUCMFprkAiCKIimgkaaKFoFIrW4QI4DJLhM4xfYn2y6rUr1FAtWQy1pFYLABIC5WnJk2xZpFRiRGMDhFtpcSvGr4U7vLMNOI44iBb3smWO9lynA3R4Y5Au6lwG0BoNkQfWglz8H92U0uUuqrXPLNkZkkOd7xqBN-bC-EL8OqbP859ix52hvwO7W-ua_0e7a1VfejN5Re5in8j |
link.rule.ids | 315,782,786,27933,27934 |
linkProvider | Ovid |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neuroprotective+action+of+halogenated+derivatives+of+L-phenylalanine&rft.jtitle=Stroke+%281970%29&rft.au=Kagiyama%2C+Tomoko&rft.au=Glushakov%2C+Alexander+V&rft.au=Sumners%2C+Colin&rft.au=Roose%2C+Brandy&rft.date=2004-05-01&rft.eissn=1524-4628&rft.volume=35&rft.issue=5&rft.spage=1192&rft.epage=1196&rft_id=info:doi/10.1161%2F01.STR.0000125722.10606.07&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0039-2499&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0039-2499&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0039-2499&client=summon |